PROK Projected Dividend Yield
Ord Cl A/ProKidney Corp ( NASDAQ : PROK )ProKidney Corp. is a clinical-stage biotechnology company. Co. is focused on cell therapy platforms capable of treating multiple chronic kidney diseases (CKD) using a patient's own cells isolated from the patient intended for treatment. Co.'s lead product candidate, Renal Autologous Cell Therapy (REACT), is designed to preserve kidney function in a CKD patient's diseased kidneys. REACT is a product that includes autologous Selected Renal Cells (SRCs) prepared from a patient's own (autologous) kidney cells. The REACT injection is an investigational therapy that is a mixture of kidney cells prepared from the participant's own kidney tissue. 20 YEAR PERFORMANCE RESULTS |
PROK Dividend History Detail PROK Dividend News PROK Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |